Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer

尿路上皮癌 医学 肿瘤科 癌症 癌症研究 内科学 膀胱癌
作者
Clara Helal,Cédric Pobel,Arnaud Bayle,Damien Vasseur,Claudio Nicotra,Félix Blanc-Durand,Natacha Naoun,Alice Bernard‐Tessier,Anna Patrikidou,Emeline Colomba,Ronan Flippot,Alina Fuerea,Nathalie Auger,Maud Ngo Camus,Benjamin Besse,Ludovic Lacroix,Étienne Rouleau,Santiago Ponce,Antoîne Italiano,Natacha Naoun
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:195: 113368-113368 被引量:4
标识
DOI:10.1016/j.ejca.2023.113368
摘要

Background Genomic stratification may help improve the management of patients with metastatic urothelial cancer (mUC), given the recent identification of targetable alterations. However, the collection of tissue samples remains challenging. Here, we assessed the clinical utility of plasma circulating tumour DNA (ctDNA) sequencing in these patients. Methods Patients with mUC were prospectively enroled in the STING trial (NCT04932525), in which ctDNA was profiled using the Foundation One Liquid CDx Assay (324 genes, blood tumour mutational burden [bTMB], microsatellite instability status). Each genomic report was reviewed by a multidisciplinary tumor board (MTB). Results Between January 2021 and June 2022, 140 mUC patients underwent molecular profiling. The median time to obtain the assay results was 20 days ((confidence interval) CI95%: [20,21]). The ctDNA analysis reproduced the somatic genomic landscape of previous tissue-based cohorts. Concordance for serial ctDNA samples was strong (r = 0.843 CI95%: [0.631–0.938], p < 0.001). At least one actionable target was detected in 63 patients (45%) with a total of 35 actionable alterations, including bTMB high (≥10 mutations/Mb) (N = 39, 21.1%), FGFR3 (N = 20, 10.8%), and Homologous recombination deficiency (HRD) alterations (N = 14, 7.6%). MTB recommended matched therapy in 63 patients (45.0%). Eight patients (5.7%) were treated, with an overall response rate of 50% (CI95%: 15.70–84.30) and a median progression-free survival (PFS) of 5.2 months (CI95%: 4.1 - NR). FGFR3 alterations were associated with a shorter PFS in patients treated with immunotherapy. Conclusion Overall, we demonstrated that genomic profiling with ctDNAs in mUC is a reliable and feasible approach for the timely initiation of genotype-matched therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ding应助凡是过往皆为序章采纳,获得10
1秒前
干净海秋完成签到,获得积分10
1秒前
小蘑菇应助zd采纳,获得10
1秒前
Ava应助别偷我增肌粉采纳,获得30
1秒前
abc完成签到,获得积分10
2秒前
一点通发布了新的文献求助10
3秒前
6秒前
淡淡的豁应助棒棒采纳,获得150
8秒前
小秋完成签到,获得积分10
8秒前
华仔应助木木林采纳,获得10
8秒前
QIZH发布了新的文献求助10
8秒前
FashionBoy应助py999采纳,获得10
9秒前
小马甲应助圆蓬蓬采纳,获得10
10秒前
10秒前
Orange应助陈念采纳,获得10
11秒前
11秒前
热心又蓝完成签到,获得积分10
12秒前
111发布了新的文献求助10
12秒前
曾经晓亦发布了新的文献求助20
12秒前
量子星尘发布了新的文献求助10
12秒前
FashionBoy应助一点通采纳,获得10
12秒前
害怕的冬云完成签到,获得积分10
13秒前
丘比特应助nni采纳,获得20
15秒前
陈一完成签到 ,获得积分10
15秒前
现代完成签到,获得积分10
16秒前
尹天奇发布了新的文献求助10
16秒前
16秒前
SYLH应助QIZH采纳,获得10
17秒前
结实的泥猴桃完成签到 ,获得积分10
18秒前
tex关闭了tex文献求助
19秒前
bkagyin应助薯条派采纳,获得10
19秒前
19秒前
19秒前
long发布了新的文献求助10
19秒前
麓麓菌完成签到 ,获得积分10
20秒前
111完成签到,获得积分10
20秒前
21秒前
向上完成签到,获得积分10
21秒前
py999发布了新的文献求助10
22秒前
zxcv完成签到 ,获得积分10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975755
求助须知:如何正确求助?哪些是违规求助? 3520108
关于积分的说明 11200829
捐赠科研通 3256492
什么是DOI,文献DOI怎么找? 1798298
邀请新用户注册赠送积分活动 877509
科研通“疑难数据库(出版商)”最低求助积分说明 806403